For research and educational purposes only. Not intended for human consumption.
Cagrilintide
Well Researched- •CagriSema Phase 3 - 22.7% weight loss
- •Dual amylin/calcitonin receptor activation
- •REDEFINE 1 & 2 trial data published
Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Overview
What is Cagrilintide?
Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist. Developed for weight management and type 2 diabetes treatment, it shows superior weight loss potential when combined with glp1-s (CagriSema), with Phase 3 trials demonstrating up to 22.7% weight reduction.
Key Benefits
FDA development candidate, extensive Phase 3 data, superior weight loss in combination with glp1-s, once-weekly convenience.
Mechanism of Action
Subcutaneous injection provides optimal bioavailability of lipidated amylin analog, targeting dual amylin and calcitonin receptors for satiety and metabolic effects.
Molecular Information
Pharmacokinetics
Research Indications
Superior Obesity Treatment
Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination, outperforming existing therapies.
Type 2 Diabetes Weight Management
15.7% weight loss in diabetic patients with concurrent glycemic improvements.
Sustained Weight Maintenance
Long-acting formulation supports sustained weight loss throughout treatment period.
Research Protocols
Disclaimer: Cagrilintide is in Phase 3 trials and not yet FDA approved. FDA approval expected Q1 2026. These protocols are based on clinical trial data.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight Loss (Monotherapy) | 2.4mg weekly | Once weekly | Subcutaneous injection |
| Weight Loss (CagriSema) | 2.4mg + glp1-s 2.4mg | Once weekly | Subcutaneous injection |
| Type 2 Diabetes Management | 2.4mg weekly | Once weekly | Subcutaneous injection with metformin |
| Dose Escalation Protocol | 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg | Weekly increases over 16 weeks | Subcutaneous injection |
Timing: Administer same day each week. Evening injection may reduce morning nausea. Can be given with or without food.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
pH CRITICAL: Cagrilintide requires acidic pH (3.5-4.5) to prevent fibril formation
Reconstitute slowly down side of vial, swirl gently (don't shake)
Verify solution is clear - any cloudiness indicates fibril formation, discard immediately
Store refrigerated (2-8°C), inspect for clarity before each injection
Allow to reach room temperature 15-30 minutes before injection
Inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pre-filled pen design
When approved, will likely be available as convenient pre-filled pen.
Pharmaceutical grade purity
Clinical trial material demonstrates >98% purity.
Frozen storage stability
Proper frozen storage at -20°C maintains stability.
Not yet commercially available
Currently only available in clinical trials - FDA approval expected Q1 2026.
Fibril formation at improper pH
Amylin analogs form fibrils at neutral/alkaline pH - solution must remain clear.
Temperature excursions
Repeated freeze-thaw cycles denature the peptide.
What to Expect
- •Week 1-2: Gastrointestinal adaptation period, mild nausea possible during dose escalation
- •Week 4-8: Early weight loss becomes apparent (2-5%), appetite reduction noticeable
- •Week 12-26: Significant weight loss acceleration (10-15%), improved satiety signals
- •Week 26+: Peak efficacy achieved (15-23% weight loss), sustained weight loss maintenance
Side Effects & Safety
Side Effects
- •Most common side effects are gastrointestinal (nausea, vomiting, diarrhea)
- •Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy
- •No clinically significant QT prolongation observed
- •Only 57.3% of patients achieved maximum 2.4mg dose in REDEFINE 1 trial
- •Formulation must be maintained at acidic pH (3.5-4.5)
When to Stop
- •Severe GI symptoms
- •Signs of allergic reaction
- •Fibril formation in solution
- •As directed by healthcare provider
References
3 StudiesREDEFINE 1 Trial (2025)
Human | 2.4mg weekly | 68 weeks | 22.7% weight loss vs 2.4% placebo
Landmark Phase 3 trial in NEJM demonstrating superior weight loss with CagriSema in 3,417 adults.
REDEFINE 2 Trial (2025)
Human | 2.4mg weekly | 68 weeks | 15.7% weight loss, 73.5% achieved HbA1c ≤6.5%
Phase 3 trial in 1,206 adults with type 2 diabetes showing significant weight loss and glycemic improvements.
Thorough QT Study (2024)
Human | 4.5mg single dose | 5 days | No clinically relevant QTc prolongation
Dedicated cardiac safety study confirming no significant QT interval prolongation.
Quick Start Guide
Research Disclaimer
Cagrilintide is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Cagrilintide must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Cagrilintide for any purpose. Consult qualified professionals for any research applications.